BioNTech SE Share Price Börse Stuttgart

Equities

22UA

US09075V1026

Biotechnology & Medical Research

Market Closed - Börse Stuttgart 10:19:13 02/05/2024 pm IST 5-day change 1st Jan Change
85.65 EUR +2.94% Intraday chart for BioNTech SE +5.94% -3.50%

Financials

Sales 2024 * 2.79B 2.99B 249B Sales 2025 * 2.72B 2.92B 243B Capitalization 20.78B 22.3B 1,859B
Net income 2024 * -562M -603M -50.27B Net income 2025 * -529M -568M -47.32B EV / Sales 2024 * 2.42 x
Net cash position 2024 * 14.03B 15.06B 1,255B Net cash position 2025 * 13.43B 14.41B 1,201B EV / Sales 2025 * 2.7 x
P/E ratio 2024 *
-36.8 x
P/E ratio 2025 *
-36.5 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.94%
Current month-3.50%
Current year-3.50%
More quotes
1 year
83.55
Extreme 83.55
115.95
3 years
83.55
Extreme 83.55
396.50
5 years
11.50
Extreme 11.5
396.50
10 years
11.50
Extreme 11.5
396.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 02/08/02
Founder 57 02/08/02
Director of Finance/CFO 60 01/21/01
Members of the board TitleAgeSince
Director/Board Member 69 01/22/01
Director/Board Member 67 02/08/02
Chairman 53 02/08/02
More insiders
Date Price Change Volume
02/24/02 85.65 +2.94% 930
30/24/30 83.2 +0.79% 128
29/24/29 82.55 +0.49% 1,562
26/24/26 82.15 +1.61% 2,807
25/24/25 80.85 -1.52% 278

Delayed Quote Börse Stuttgart, May 02, 2024 at 10:19 pm IST

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
86.22 EUR
Average target price
107 EUR
Spread / Average Target
+24.13%
Consensus